San Diego, California--(Newsfile Corp. - September 26, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce that shareholders have approved all matters put forward at its Annual and Special Meeting ("ASM") held on September 19th, 2022.
All five members of the Company's board of directors, Dr. Patrice Rioux, Dr. Christopher Starr, Kim Tsuchimoto, Hogan Mullally and Brook Riggins, named as nominees in the Company's management information circular dated August 15, 2022, were elected as directors:
Additional voting results from the ASM include the following:
- Shareholders approved the re-appointment of MNP LLP, Chartered Professional Accountants as the Company's auditor,
- Disinterested shareholders approved the Company's 2022 Stock Option Plan ('Stock Option Plan Resolution') as set out in the management information circular.
About Thiogenesis
Thiogenesis Therapeutics, Corp. (TSXV: TTI), is a clinical-stage biopharmaceutical company operating through its wholly subsidiary based in San Diego, CA. The Company is publicly traded on the TSX Venture Exchange. Thiogenesis is developing sulfur-containing therapeutics that are thiol-active compounds and that potentially treat serious pediatric diseases with unmet clinical needs. Its lead compound, TTI-0102, was developed to address the challenges of thiol-active drugs; which are their short half-lives, dosing limitations and discomforting side effects. The Company's initial target indications include Mitochondrial Encephalopathy Lactic Acidosis and Stroke (MELAS) and Rett's syndrome.
For further information, please contact:
Brook Riggins, Director and CFO
Email: briggins@thiogenesis.com
Telephone +420-726-659-259
Forward-Looking Statements
This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as "forward- looking statements") within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/138354
